The effects of Xuefu Zhuyu and Shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: A randomised controlled clinical trial

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Xing, Yanwei ^a   Wang, Jie ^a   Yang, Xiaochen ^a   Chu, Fuyong ^b   Chen, Jianxin ^c   He, Qingyong ^a   Yao, Kuiwu ^a   Teng, Fei ^a   Gao, Yonghong ^c   Xing, Yanhui ^a   Wu, Aiming ^c  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b BEIJING HOSPITAL OF TRADITIONAL CHINESE MEDICINE AFFILIATED TO CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHINESE DRUG; CLOPIDOGREL; ENDOTHELIN 1; ENOXAPARIN; GELATINASE B; HIGH SENSITIVITY C REACTIVE PROTEIN; HOMOCYSTEINE; METOPROLOL TARTRATE; PLACEBO; SHENGMAI; UNCLASSIFIED DRUG; XUEFU ZHUYU;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG CAPSULE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QI DEFICIENCY SYNDROME; QI STAGNATION SYNDROME; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; YANG DEFICIENCY; YIN DEFICIENCY;

EID: 84878683499     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/896467     Document Type: Article

References (41)

1. Yangfeng W., Current status of major cardiovascular risk factors in Chinese populations and their trends in the past two decades. Chinese Journal of Cardiology 2001 29 2 74 79
2. Rosamond W., Flegal K., Furie K., Heart disease and stroke statistics-2008 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2008 117 4 e25 e146 2-s2.0-77954587937 10.1161/CIR.0b013e3181e65b27
3. Grech E. D., ABC of interventional cardiology: percutaneous coronary intervention. II: the procedure. British Medical Journal 2003 326 7399 1137 1140 2-s2.0-0037900982 (Pubitemid 36613454)
4. Ma X., Wu T., Robich M. P., Drug-eluting stents. International Journal of Clinical and Experimental Medicine,2010 3 3 192 201
5. Aziz S., Morris J. L., Perry R. A., Late stent thrombosis associated with coronary aneurysm formation after sirolimus-eluting stent implantation. Journal of Invasive Cardiology 2007 19 4 E96 E98 2-s2.0-34147172684 (Pubitemid 46558007)
6. Kim H. L., Park K. W., Kwak J. J., Kim Y. S., Sir J. J., Lee S. J., Lee H. Y., Chang H. J., Kang H. J., Cho Y. S., Chung W. Y., Chae I. H., Choi D. J., Kim H. S., Oh B. H., Park Y. B., Koo B. K., Stent-related cardiac events after non-cardiac surgery: drug-eluting stent versus bare metal stent. International Journal of Cardiology 2008 123 3 353 354 2-s2.0-37449023375 10.1016/j.ijcard. 2006.11.182
7. Camenzind E., Treatment of in-stent restenosis-back to the future? New England Journal of Medicine 2006 355 20 2149 2151 2-s2.0-33751003791 10.1056/NEJMe068215 (Pubitemid 44749325)
8. Pfisterer M. E., Richartz B., Silber S., The BASKET-LATE study: basel stent cost-effectiveness trial-late thrombotic events trial. Herz 2006 31 3 259 2-s2.0-33745129402 10.1007/s00059-006-2828-4 (Pubitemid 43892443)
9. Ten Berg J. M., Thijs Plokker H. W., Verheugt F. W. A., Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention. Current Controlled Trials in Cardiovascular Medicine 2001 2 3 129 140 2-s2.0-0034953515 (Pubitemid 32600518)
10. Keji C., Hao X., The integration of traditional Chinese medicine and Western medicine. European Review 2003 11 2 225 235 2-s2.0-0038115317 10.1017/S106279870300022X (Pubitemid 36715496)
11. Chen B. J., Pan Z. Q., Su X. X., Study on changes of TCM syndrome in patients with coronary heart disease before and after intervention treatment. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007 27 8 689 691 2-s2.0-58149095578
12. Zheng G. L., Wang S. H., Clinical effect and mechanismn of xuefu zhuyu capsule in treating unstable angina pectoris. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009 29 1 65 68 2-s2.0-73449108504
13. Wang X. Y., Lou Y., Combination of XuefuZhuyu decoction with western medicine for unstable angina in 56 cases with coronary heart disease. Tianjin Journal of Traditional Chinese Medicine 2009 26 6 521
14. Cai F. S., Observation on clinical therapeutic effect of Xuefuzhuyu Capsules in treating angina pectoris. Journal of Liaoning University of Traditional Chinese Medicine 2009 11 8 128 129
15. Li Y. R., Zhang H. F., Du J., SU D. W., Clinical observation of XuefuZhuyu Capsule for unstable angina in patients with coronary heart disease. Journal of Liaoning University of Traditional Chinese Medicine 2008 10 11 103 104
16. Song J., Chen W. Y., Wu L. Y., Zheng L. P., Lin W., Gao D., Kaptchuk T. J., Chen K. J., A microarray analysis of angiogenesis modulation effect of Xuefu Zhuyu Decoction on endothelial cells. Chinese Journal of Integrative Medicine 2012 18 7 502 506
17. Zhang Q. Y., Wang Q. L., Su J. F., Angiogenesis effects of Xuefu Zhuyu Decoction and VEGF protein expression of rats with acute myocardial Ischemia. Chinese Journal of Information on Traditional Chinese Medicine 2011 18 2 53 54
18. Braunwald E., Antman E. M., Beasley J. W., ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000 102 10 1193 1209
19. Specialty Committee of Activating Blood and Removing Stasis CAOIM, Diagnostic standard of blood stasis syndrome. Chinese Journal of Integrated Traditional and Western Medicine 1987 7 3
20. Shen Z., Wang W., Standards reference of TCM deficiency syndrome. Chinese Journal of Integrated Traditional and Western Medicine 1986 1986 10 598
21. Zhang M. Z., Wang L., The academic ideology of DENG TieTao treatment of sydroms after PCI based on syndrome differentiation. Journal of Traditional Chinese Medicine 2006 14 1 32 33
22. Shroff G. R., Cen Y. Y., Duprez D. A., Bart B. A., Relationship between carotid artery stiffness index, BNP and high-sensitivity CRP. Journal of Human Hypertension 2009 23 12 783 787 2-s2.0-70749148531 10.1038/jhh.2009.17
23. Rost N. S., Wolf P. A., Kase C. S., Kelly-Hayes M., Silbershatz H., Massaro J. M., D'Agostino R. B., Franzblau C., Wilson P. W. F., Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study. Stroke 2001 32 11 2575 2579 2-s2.0-0035170373 (Pubitemid 33055308)
24. Koenig W., Sund M., Fröhlich M., Fischer H. G., Löwel H., Döring A., Hutchinson W. L., Pepys M. B., C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 1999 99 2 237 242 2-s2.0-0032923669 (Pubitemid 29056365)
25. Verma S., Wang C. H., Li S. H., Dumont A. S., Fedak P. W. M., Badiwala M. V., Dhillon B., Weisel R. D., Li R. K., Mickle D. A. G., Stewart D. J., A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002 106 8 913 919 2-s2.0-0037143638 10.1161/01.CIR.0000029802.88087.5E (Pubitemid 34925323)
26. Falk E., Shah P. K., Fuster V., Coronary plaque disruption. Circulation 1995 92 3 657 671 2-s2.0-0029090411
27. Zeiher A. M., Goebel H., Schachinger V., Ihling C., Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995 91 4 941 947 2-s2.0-0028929453
28. Zhang X., Zhao F., Xu C., Lu C., Jin H., Chen S., Qian R., Circadian rhythm disorder of thrombosis and thrombolysis-related gene expression in apolipoprotein E knock-out mice. International Journal of Molecular Medicine 2008 22 2 149 153 2-s2.0-48749115617 10.3892/ijmm-00000002
29. Katayama T., Yano K., Nakashima H., Takagi C., Honda Y., Suzuki S., Iwasaki Y., Clinical significance of acute-phase endothelin-1 in acute myocardial infarction patients treated with direct coronary angioplasty. Circulation Journal 2005 69 6 654 658 2-s2.0-20444389442 10.1253/circj.69.654 (Pubitemid 40806102)
30. Yip H. K., Wu C. J., Chang H. W., Yang C. H., Yu T. H., Chen Y. H., Hang C. L., Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest 2005 127 5 1491 1497 2-s2.0-19844364299 10.1378/chest.127.5.1491 (Pubitemid 46218771)
31. Pasterkamp G., Schoneveld A. H., Hijnen D. J., De Kleijn D. P. V., Teepen H., Van Der Wal A. C., Borst C., Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000 150 2 245 253 2-s2.0-0034074887 10.1016/S0021-9150(99)00371-8 (Pubitemid 30336536)
32. Brown D. L., Hibbs M. S., Kearney M., Loushin C., Isner J. M., Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation 1995 91 8 2125 2131 2-s2.0-0028906790
33. Sarén P., Welgus H. G., Kovanen P. T., TNF- α and IL-1 β selectively induce expression of 92-kDa gelatinase by human macrophages. Journal of Immunology 1996 157 9 4159 4165 2-s2.0-0030292766 (Pubitemid 126449330)
34. Kim S. H., Kang Y. J., Kim W. J., Woo D. K., Lee Y., Kim D. I., Park Y. B., Kwon B. S., Park J. E., Lee W. H., TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circulation Journal 2004 68 4 396 399 2-s2.0-11144353779 10.1253/circj.68.396 (Pubitemid 38470720)
35. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., Ueno T., Sugi K., Imaizumi T., Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. Journal of the American College of Cardiology 1998 32 2 368 372 2-s2.0-0032145662 10.1016/S0735-1097(98)00250-2 (Pubitemid 28396484)
36. Kalela A., Koivu T. A., Sisto T., Kanervisto J., Höyhtyä M., Sillanaukee P., Lehtimäki T., Nikkari S. T., Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation 2002 62 5 337 342 2-s2.0-0036394073 10.1080/00365510260296483
37. Blankenberg S., Rupprecht H. J., Poirier O., Bickel C., Smieja M., Hafner G., Meyer J., Cambien F., Tiret L., Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003 107 12 1579 1585 2-s2.0-0037381597 10.1161/01.CIR.0000058700.41738.12 (Pubitemid 36397324)
38. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., Okumura K., Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. American Heart Journal 2001 141 2 211 217 2-s2.0-0035147051 10.1067/mhj.2001.112238 (Pubitemid 32128725)
39. Funayama H., Ishikawa S. E., Kubo N., Katayama T., Yasu T., Saito M., Kawakami M., Increases in interleukin-6 and matrix metalloproteinase-9 in the infarct-related coronary artery of acute myocardial infarction. Circulation Journal 2004 68 5 451 454 2-s2.0-2442670066 10.1253/circj.68.451 (Pubitemid 38657534)
40. Aksungar F. B., Topkaya A. E., Akyildiz M., Interleukin-6, C-reactive protein and biochemical parameters during prolonged intermittent fasting. Annals of Nutrition and Metabolism 2007 51 1 88 95 2-s2.0-34247483580 10.1159/000100954 (Pubitemid 46646621)
41. Graham L. M., Daly L. E., Refsum H. M., Robinson K., Brattström L. E., Ueland P. M., Palma-Reis R. J., Boers G. H. J., Sheahan R. G., Lsraelsson B., Uiterwaal C. S., Meleady R., McMaster D., Verhoef P., Witteman J., Rubba P., Bellet H., Wautrecht J. C., De Valk H. W., Sales Lúis A. C., Parrot-Roulaud F. M., Tan K. S., Higgins I., Garcon D., Medrano M. J., Candito M., Evans A. E., Andria G., Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. Journal of the American Medical Association 1997 277 22 1775 1781 2-s2.0-1842331509 (Pubitemid 27247163)